Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data

BACKGROUND: This phase I/II trial in patients with recurrent glioblastoma (GBM) evaluates the safety and preliminary efficacy of marizomib, an irreversible pan-proteasome inhibitor that crosses the blood–brain barrier. METHODS: Part A assessed the safety and efficacy of marizomib monotherapy. In Par...

Descripción completa

Detalles Bibliográficos
Autores principales: Bota, Daniela A, Mason, Warren, Kesari, Santosh, Magge, Rajiv, Winograd, Benjamin, Elias, Ileana, Reich, Steven D, Levin, Nancy, Trikha, Mohit, Desjardins, Annick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557653/
https://www.ncbi.nlm.nih.gov/pubmed/34729484
http://dx.doi.org/10.1093/noajnl/vdab142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8557653/
https://www.ncbi.nlm.nih.gov/pubmed/34729484
http://dx.doi.org/10.1093/noajnl/vdab142

Ejemplares similares